Filtered By:
Specialty: Drugs & Pharmacology
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 121044 results found since Jan 2013.
Transforming drug discovery with a high-throughput AI-powered platform: a 5-year experience with Patrimony
Drug Discov Today. 2023 Sep 15:103772. doi: 10.1016/j.drudis.2023.103772. Online ahead of print.ABSTRACTHigh-throughput computational platforms are being established to accelerate drug discovery. Servier launched the Patrimony platform to harness computational sciences and artificial intelligence (AI) to integrate massive multimodal data from internal and external sources. Patrimony has enabled researchers to prioritize therapeutic targets based on a deep understanding of the pathophysiology of immuno-inflammatory diseases. Herein, we share our experience regarding main challenges and critical success factors faced when in...
Source: Drug Discovery Today - September 17, 2023 Category: Drugs & Pharmacology Authors: Fran çois-Xavier Blaudin de Thé Claire Baudier Renan Andrade Pereira C éline Lefebvre Philippe Moingeon Patrimony Working Group Source Type: research
Effervescent tablet-assisted deep eutectic solvent based on magnetic nanofluid for liquid phase microextraction of tyrosine kinase inhibitors in plasma samples by high-performance liquid chromatography
CONCLUSIONS: The developed method displayed high sensitivity, low consumption of solvent, low cost, simplicity, high recoveries, short extraction time, and good repeatability for determination of three anti-cancer drugs in human plasma samples.PMID:37717246 | DOI:10.1007/s43440-023-00524-x
Source: Pharmacological Reports - September 17, 2023 Category: Drugs & Pharmacology Authors: Khosrou Abdi Maryam Ezoddin Laleh Adlnasab Bahar Aziz Kabiri Mohammad Ali Karimi Somaye Behnamipour Houman Alimoradi Source Type: research
Intratumoral injection of melatonin enhances tumor regression in cell line-derived and patient-derived xenografts of head and neck cancer by increasing mitochondrial oxidative stress
Biomed Pharmacother. 2023 Sep 15;167:115518. doi: 10.1016/j.biopha.2023.115518. Online ahead of print.ABSTRACTHead and neck squamous cell carcinoma present a high mortality rate. Melatonin has been shown to have oncostatic effects in different types of cancers. However, inconsistent results have been reported for in vivo applications. Consequently, an alternative administration route is needed to improve bioavailability and establish the optimal dosage of melatonin for cancer treatment. On the other hand, the use of patient-derived tumor models has transformed the field of drug research because they reflect the heterogenei...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 17, 2023 Category: Drugs & Pharmacology Authors: Laura Martinez-Ruiz Javier Florido C ésar Rodriguez-Santana Alba L ópez-Rodríguez Ana Guerra-Librero Beatriz I Fern ández-Gil Patricia Garc ía-Tárraga Jos é Manuel Garcia-Verdugo Felix Oppel Holger Sudhoff David S ánchez-Porras Amadeo Ten-Steve Jo Source Type: research
Polyphyllin VII alleviates pulmonary hypertension by inducing miR-205-5p to target the β-catenin pathway
CONCLUSION: PP7 likely modulates β-catenin protein levels by promoting miR-205-5p expression, thereby alleviating PH, vascular remodeling and airway smooth muscle remodeling.PMID:37717533 | DOI:10.1016/j.biopha.2023.115516
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 17, 2023 Category: Drugs & Pharmacology Authors: Fangyun Zhao Chunhong Pan Yue Zhang Jiao Yang Xiqian Xing Source Type: research
Optimising antithrombotic therapy after ACS and PCI
Vascul Pharmacol. 2023 Sep 15:107228. doi: 10.1016/j.vph.2023.107228. Online ahead of print.ABSTRACTDual antiplatelet therapy, combining aspirin with a platelet P2Y12 receptor inhibitor, is the standard treatment for acute coronary syndrome patients undergoing percutaneous coronary intervention. The optimal type and duration of dual antiplatelet therapy depend on the patient's risk for ischemic and hemorrhagic complications. De-escalation strategies, such as switching to a less potent P2Y12 inhibitor, reducing the dose, or discontinuing one of the antiplatelet agents, may be suitable for high-risk bleeding patients with lo...
Source: Vascular Pharmacology - September 17, 2023 Category: Drugs & Pharmacology Authors: Davide Capodanno Source Type: research
NAP1L5 facilitates pancreatic ductal adenocarcinoma progression via TRIM29-mediated ubiquitination of PHLPP1
Biochem Pharmacol. 2023 Sep 15:115811. doi: 10.1016/j.bcp.2023.115811. Online ahead of print.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is considered one of the most aggressive solid tumours in humans. Despite its high mortality rate, effective targeted therapeutic strategies remain limited due to incomplete understanding of the underlying biological mechanisms. The NAP1L gene family has been implicated in the development and progression of various human tumours. However, the specific function and role of NAP1L5 (nucleosome assembly protein-like 5) in PDAC have not been fully elucidated. Therefore, in this study, we a...
Source: Biochemical Pharmacology - September 17, 2023 Category: Drugs & Pharmacology Authors: Benli Xiao Yuzhen Ge Rui Zhao Yewei Zhang Yi Guo Shilong Zhang Bo Li Peng Qiu Zheng Chao Shi Zuo Source Type: research
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia
Biochem Pharmacol. 2023 Sep 15:115809. doi: 10.1016/j.bcp.2023.115809. Online ahead of print.ABSTRACTAlthough a great cure rate has been achieved for pediatric BCP-ALL, approximately 15% of patients do not respond to conventional chemotherapy and experience disease relapse. A major effort to improve the cure rates by treatment intensification would result in an undesirable increase in treatment-related toxicity and mortality, raising the need to identify novel therapeutic approaches. High-throughput (HTP) drug screening enables the profiling of patients' responses in vitro and allows the repurposing of compounds currently ...
Source: Biochemical Pharmacology - September 17, 2023 Category: Drugs & Pharmacology Authors: Athanasios Oikonomou Luigia Valsecchi Manuel Quadri Titus Watrin Katerina Scharov Simona Procopio Jia-Wey Tu Melina Vogt Angela Maria Savino Daniela Silvestri Maria Grazia Valsecchi Andrea Biondi Arndt Borkhardt Sanil Bhatia Giovanni Cazzaniga Grazia Fazi Source Type: research
Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis
Biochem Pharmacol. 2023 Sep 15:115810. doi: 10.1016/j.bcp.2023.115810. Online ahead of print.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) remains one of the most devastating diseases; it has a considerably poor prognosis and may become the second most lethal malignancy in the next 10 years. Chemotherapeutic resistance is common in PDAC; thus, it is necessary to exploit effective alternative drugs. In recent years, traditional folk medicines and their extracts have shown great potential in cancer treatment. The seed of Lagenaria siceraria (Molina) Standl. is a traditional medicine in Asia. Because of its analgesic effect...
Source: Biochemical Pharmacology - September 17, 2023 Category: Drugs & Pharmacology Authors: Dongchao Xu Ajuan Liu Qiang Liu Hongchen Zhang Mengyao Tian Ying Bian Xiaofeng Zhang Meidan Ying Hongzhang Shen Source Type: research
Intratumoral injection of melatonin enhances tumor regression in cell line-derived and patient-derived xenografts of head and neck cancer by increasing mitochondrial oxidative stress
Biomed Pharmacother. 2023 Sep 15;167:115518. doi: 10.1016/j.biopha.2023.115518. Online ahead of print.ABSTRACTHead and neck squamous cell carcinoma present a high mortality rate. Melatonin has been shown to have oncostatic effects in different types of cancers. However, inconsistent results have been reported for in vivo applications. Consequently, an alternative administration route is needed to improve bioavailability and establish the optimal dosage of melatonin for cancer treatment. On the other hand, the use of patient-derived tumor models has transformed the field of drug research because they reflect the heterogenei...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 17, 2023 Category: Drugs & Pharmacology Authors: Laura Martinez-Ruiz Javier Florido C ésar Rodriguez-Santana Alba L ópez-Rodríguez Ana Guerra-Librero Beatriz I Fern ández-Gil Patricia Garc ía-Tárraga Jos é Manuel Garcia-Verdugo Felix Oppel Holger Sudhoff David S ánchez-Porras Amadeo Ten-Steve Jo Source Type: research
Polyphyllin VII alleviates pulmonary hypertension by inducing miR-205-5p to target the β-catenin pathway
CONCLUSION: PP7 likely modulates β-catenin protein levels by promoting miR-205-5p expression, thereby alleviating PH, vascular remodeling and airway smooth muscle remodeling.PMID:37717533 | DOI:10.1016/j.biopha.2023.115516
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 17, 2023 Category: Drugs & Pharmacology Authors: Fangyun Zhao Chunhong Pan Yue Zhang Jiao Yang Xiqian Xing Source Type: research
Ozone in the ischemia/reperfusion (I/R) injury. Lessons for ozone therapy in myocardial ischemia
Biomed Pharmacother. 2023 Sep 15;167:115482. doi: 10.1016/j.biopha.2023.115482. Online ahead of print.NO ABSTRACTPMID:37717532 | DOI:10.1016/j.biopha.2023.115482
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 17, 2023 Category: Drugs & Pharmacology Authors: Salvatore Chirumbolo Marianno Franzini Luigi Valdenassi Sergio Pandolfi Source Type: research
Itaconate: A promising precursor for treatment of neuroinflammation associated depression
This article provides an overview of the immunomodulatory effects of itaconate and its potential therapeutic efficacy in inflammatory depression, focusing on the promising application of itaconate as a precursor of antidepressants.PMID:37717531 | DOI:10.1016/j.biopha.2023.115521
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 17, 2023 Category: Drugs & Pharmacology Authors: Ruisi Liu Yueling Gong Chenyi Xia Yemin Cao Cheng Zhao Mingmei Zhou Source Type: research
TAT Decorated siRNA Polyplexes For Inhalation Delivery in Anti-asthma Therapy
Eur J Pharm Sci. 2023 Sep 15:106580. doi: 10.1016/j.ejps.2023.106580. Online ahead of print.ABSTRACTIn this work, a novel protonable copolymer was designed to deliver siRNA through the inhalation route, as an innovative formulation for the management of asthma. This polycation was synthesized by derivatization of α,β-poly(N-2-hydroxyethyl)D,L-aspartamide (PHEA) first with 1,2-Bis(3-aminopropylamino)ethane (bAPAE) and then with a proper amount of maleimide terminated poly(ethylene glycol) (PEG-MLB), with the aim to increase the superficial hydrophilicity of the system, allowing the diffusion trough the mucus layer. Once t...
Source: European Journal of Pharmaceutical Sciences - September 17, 2023 Category: Drugs & Pharmacology Authors: Salvatore Emanuele Drago Marta Cabibbo Emanuela Fabiola Craparo Gennara Cavallaro Source Type: research
Recent engineering advances of EVs for compounds, nucleic acids, and TCM delivery
Eur J Pharm Sci. 2023 Sep 15:106584. doi: 10.1016/j.ejps.2023.106584. Online ahead of print.ABSTRACTExtracellular vesicles (EVs) are phospholipid bilayer nano-vesicles that were originally identified to deliver signals for intercellular communications. Based on the dynamic contents including proteins, nucleic acids and metabolites, EVs have been developed into diagnostic and therapeutic fields including cardiovascular diseases, neurological disorders and infectious diseases. A growing number of investigations revealed that EVs are also powerful carriers of loaded compounds and nucleic acids as enhanced treatments. Herein, ...
Source: European Journal of Pharmaceutical Sciences - September 17, 2023 Category: Drugs & Pharmacology Authors: Yunfeng Di Wei Wang Yong Wang Jingyu Wang Source Type: research
Attenuation of celecoxib cardiac toxicity using Poly( δ-decalactone) based nanoemulsion via oral route
Eur J Pharm Sci. 2023 Sep 15:106585. doi: 10.1016/j.ejps.2023.106585. Online ahead of print.ABSTRACTCelecoxib (CLX), a poorly soluble anti-inflammatory drug, requires administration in higher concentrations to produce therapeutic effects, oftentimes resulting in cardiac toxicity. Therefore, in this study, we employed a nanoemulsion technology to improve the solubility of CLX using poly(δ-decalactone) (PDL) polymer as an oil and mPEG-b-PDL as a surfactant. The nanoemulsion (NE) was successfully prepared via the nanoprecipitation method. In vitro characterization was performed for size, drug release, and stability. In vivo ...
Source: European Journal of Pharmaceutical Sciences - September 17, 2023 Category: Drugs & Pharmacology Authors: Saurabh Maru Jyoti Verma Carl-Eric Wilen Jessica M Rosenholm Kuldeep K Bansal Source Type: research
